NCT04319783
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04319783
Title Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA (DECREASE)
Acronym DECREASE
Recruitment Active, not recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors Trans Tasman Radiation Oncology Group
Indications
Therapies
Age Groups: senior | adult
Covered Countries AUS

Facility Status City State Zip Country Details
St Vincent's Hospital Darlinghurst New South Wales 2101 Australia Details
GenesisCare Hurstville Hurstville New South Wales 2220 Australia Details
GenesisCare North Shore Saint Leonards New South Wales 2065 Australia Details
Calvary Mater Newcastle Waratah New South Wales 2298 Australia Details
Royal Brisbane and Women's Hospital Herston Queensland 4006 Australia Details
Princess Alexandra Hospital (ROPART) Raymond Terrace Queensland 4101 Australia Details
Princess Alexandra Hospital (ROPAIR) Woolloongabba Queensland 4102 Australia Details
Royal Adelaide Hospital Adelaide South Australia 5000 Australia Details
Royal Hobart Hospital Hobart Tasmania 7000 Australia Details
Peter MacCallum Cancer Centre, Bendigo Bendigo Victoria 3550 Australia Details
Peter MacCallum Cancer Centre, Box Hill Box Hill Victoria 3128 Australia Details
Peter MacCallum Cancer Centre, Parkville Melbourne Victoria 3002 Australia Details
Icon Cancer Centre Epworth Richmond Victoria 3121 Australia Details
Western Health St Albans Victoria 3021 Australia Details
GenesisCare Fiona Stanley Hospital Murdoch Western Australia 6150 Australia Details
National Cancer Centre Singapore Singapore 168583 Singapore Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field